netoglitazone

Also Known As:

2,4-thiazolidinedione, 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-; 5-((6-((2-fluorophenyl)methoxy)-2-naphthalenyl)methyl)-2,4-thiazolidinedione; MCC 555; MCC-555; PGX 510; PGX-510; RWJ-241947; RWJ241947; isaglitazone

Networked: 16 relevant articles (4 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - Thiazolidinediones: 2250
      - netoglitazone: 16
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - Thiazolidinediones: 2250
        netoglitazone: 16

Experts

1.	Baek, Seung Joon: 6 articles (09/2013 - 05/2006)
2.	Cekanova, Maria: 3 articles (07/2010 - 04/2008)
3.	Imchen, Temjenmongla: 2 articles (09/2013 - 09/2012)
4.	Min, Kyung-Won: 2 articles (09/2013 - 09/2012)
5.	Lee, Seong-Ho: 2 articles (07/2010 - 05/2006)
6.	McEntee, Michael F: 2 articles (07/2010 - 09/2008)
7.	Fan, Guorong: 2 articles (04/2009 - 03/2009)
8.	Lin, Mei: 2 articles (04/2009 - 03/2009)
9.	Lu, Guocai: 2 articles (04/2009 - 03/2009)
10.	Sun, Ning: 2 articles (04/2009 - 03/2009)

Related Diseases

1.	Insulin Resistance 10/01/1998 - "5. In conclusion, chronic MCC-555 treatment of young ZDF rats displaying IGT attenuates the development of overt diabetes through improved insulin sensitivity and maintenance of beta-cell function. " 12/01/1998 - "MCC-555 may prove a useful compound for alleviating the metabolic disturbances and IGT associated with insulin resistance in man." 12/01/1998 - "4. In conclusion, we have demonstrated that MCC-555 improves metabolic status and insulin sensitivity in obese Zucker and diabetic ZDF rats. " 10/01/1998 - "4. The hyperinsulinaemic-euglycaemic clamp technique was applied to all rats after treatment to examine the effects of MCC-555 on insulin sensitivity. " 12/01/1998 - "Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555."
2.	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/01/2013 - "Dual ligands for PPARα and PPARγ, such as netoglitazone (MCC-555), have been developed to improve treatment of metabolic syndromes, including hyperglycemia and hyperlipidemia. " 06/01/2007 - "Currently, PPAR-delta agonists (GW501516 in Phase I trials), partial PPAR-gamma agonists (metaglidasen in Phase II and III trials), and pan agonists (alpha, gamma, delta; netoglitazone in Phase II and III trials) with improved cell and tissue selectivity are undergoing investigation to address multiple aspects of the metabolic syndrome with a single medication. "
3.	Neoplasms (Cancer) 09/01/2008 - "In agreement with in vitro studies, enhanced Muc2 expression was observed in the small intestinal tumors of Min mice treated with MCC-555, suggesting that MUC2 expression may be associated at least in part with the antitumorigenic action of MCC-555. " 02/15/2004 - "Small, well-defined clinical studies using RWJ-241947 are in order for these cancers." 09/01/2012 - "MCC-555 also has anti-proliferative activity through growth inhibition and apoptosis induction in several cancer cell types. " 02/15/2004 - "Remarkably, in vivo treatment of male beige/nude/X-linked immunodeficient (BNX) mice with RWJ-241947 profoundly suppressed growth of PC-3 prostate cancer xenografts with prominent apoptosis, as well as fibrosis, including inflammatory and giant cell reaction in the remaining tumor tissue. " 09/01/2008 - "Overall, these results indicate that MCC-555 has a potent tumor suppressor activity in intestinal tumorigenesis, likely involving MUC2 up-regulation by ERK and PPARgamma pathways."
4.	Carcinogenesis 09/01/2013 - "Our data clearly suggest that MCC-555 has an effect on the early events of colon carcinogenesis, thus providing evidence that MCC-555 could be a potential preventive compound for CRC. " 09/01/2013 - "In this study, chemopreventive properties of MCC-555 in colorectal tumorigenesis were evaluated using azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) in A/J mice. " 09/01/2008 - "Overall, these results indicate that MCC-555 has a potent tumor suppressor activity in intestinal tumorigenesis, likely involving MUC2 up-regulation by ERK and PPARgamma pathways." 09/01/2013 - "Characterization of PPAR dual ligand MCC-555 in AOM-induced colorectal tumorigenesis." 09/01/2012 - "Our group has shown that MCC-555 targets several proteins in colorectal tumorigenesis including nonsteroidal anti-inflammatory drug (NSAID)-activated gene (NAG-1) which plays an important role in chemoprevention responsible for chemopreventive compounds. "
5.	Colorectal Neoplasms (Colorectal Cancer) 05/01/2006 - "These findings may provide a novel explanation for the antitumorigenic and/or proapoptotic action of MCC-555 in human colorectal cancer and the ability of pharmacologic approaches to be used against diseases caused by alterations of RNA stability." 04/01/2008 - "In the present study, we examined the alteration of gene expression in HCT-116 human colorectal cancer cells by PPARgamma agonists: MCC-555 (5 microM), rosiglitazone (5 microM), and 15-deoxy-Delta12,14-prostaglandin J2 (1 microM). " 07/10/2010 - "To elucidate the molecular mechanism(s), by which MCC-555 exerts its effects on the human colorectal cancer cells, we have analyzed the expression of two pro-apoptotic proteins, Krüppel-like factor 4 (KLF4) and nonsteroidal anti-inflammatory drug (NSAID)-activated gene-1 (NAG-1). " 05/01/2006 - "The thiazolidinedione derivative MCC-555 has an apoptotic activity in human colorectal cancer cells, accompanied by up-regulation of a proapoptotic nonsteroidal anti-inflammatory drug-activated gene (NAG-1) in a PPARgamma-independent manner. " 05/01/2006 - "A novel peroxisome proliferator-activated receptor gamma ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells."

Related Drugs and Biologics

1.	PPAR-gamma Agonists
2.	PPAR delta
3.	GW 501516
4.	2,4-thiazolidinedione (thiazolidinedione)
5.	Glucose (Dextrose)
6.	Insulin (Novolin)
7.	PPAR gamma
8.	Azoxymethane
9.	Androgens
10.	Rosiglitazone (Avandia)

Related Therapies and Procedures

1.	Chemoprevention
2.	Therapeutics
3.	Aftercare (After-Treatment)